Difficulty: Medium
Average Score: 73%
Testbank
After reporting abdominal pain, the patient has blood drawn for a CA-19-9. When he asks the nurses the purpose of this test, which response is appropriate?
Correct answer
A
Rationale
It tests for hepatobiliary cancer.
CA 19-9 is a tumor marker primarily associated with hepatobiliary cancers, including pancreatic cancer and cholangiocarcinoma. Elevated levels of CA 19-9 can indicate the presence of these cancers, making it relevant in assessing patients with abdominal pain and potential hepatobiliary issues.
B: It tests for colorectal cancer. CA 19-9 is not a specific marker for colorectal cancer; instead, carcinoembryonic antigen (CEA) is more commonly used for that purpose.
C: It tests for bladder cancer. CA 19-9 is not associated with bladder cancer, which typically uses markers like NMP22 or UroVysion for diagnosis and monitoring.
D: It tests for lung cancer. CA 19-9 does not serve as a marker for lung cancer, which is generally evaluated using different tumor markers such as CEA or cytokeratin 19 fragments.
CA 19-9 is a tumor marker primarily associated with hepatobiliary cancers, including pancreatic cancer and cholangiocarcinoma. Elevated levels of CA 19-9 can indicate the presence of these cancers, making it relevant in assessing patients with abdominal pain and potential hepatobiliary issues.
B: It tests for colorectal cancer. CA 19-9 is not a specific marker for colorectal cancer; instead, carcinoembryonic antigen (CEA) is more commonly used for that purpose.
C: It tests for bladder cancer. CA 19-9 is not associated with bladder cancer, which typically uses markers like NMP22 or UroVysion for diagnosis and monitoring.
D: It tests for lung cancer. CA 19-9 does not serve as a marker for lung cancer, which is generally evaluated using different tumor markers such as CEA or cytokeratin 19 fragments.